Systimmune reported that izalontamab brengitecan (iza‑bren), its next‑generation antibody‑drug conjugate, met both progression‑free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple‑negative breast cancer. The readout supports the drug’s licensing relationship with Bristol Myers Squibb and positions iza‑bren as a potential new option in a hard‑to‑treat population. The company highlighted the positive survival data as a regulatory and commercial inflection point for the program.